https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-02-20 / Front Immunol 2024;15:1368103
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-02-20 / Front Immunol 2024;15:13681032024-02-20 00:00:002024-02-20 00:00:00Dendritic cell vaccination combined with carboplatin/paclitaxel for metastatic endometrial cancer patients: results of a phase I/II trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-11-18 / Cancers (Basel) 2021 Nov;13(22)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-11-18 / Cancers (Basel) 2021 Nov;13(22)2021-11-18 00:00:002021-11-18 00:00:00A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-08-01 / Anticancer Res 2020 Aug;40(8):4729-4740
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-08-01 / Anticancer Res 2020 Aug;40(8):4729-47402020-08-01 00:00:002023-01-23 10:19:18Prognostic Factors for Endometrial and Cervical Cancers of Uterus Treated With Immune-cell Therapy: A Retrospective Study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-10-01 / Gan To Kagaku Ryoho 2014 Oct;41(10):1295-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-10-01 / Gan To Kagaku Ryoho 2014 Oct;41(10):1295-72014-10-01 00:00:002014-10-01 00:00:00[The effect of immunotherapy and hyperthermia on advanced or recurrent ovarian and uterine cancer – 229 clinical cases]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-01 / Hum Vaccin Immunother 2014;10(7):1822-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-01 / Hum Vaccin Immunother 2014;10(7):1822-72014-01-01 00:00:002024-03-18 11:00:32Dendritic cell immunotherapy in uterine cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-12-01 / Anticancer Res 2013 Dec;33(12):5495-500
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-12-01 / Anticancer Res 2013 Dec;33(12):5495-5002013-12-01 00:00:002024-03-18 10:53:49Wilms‘ Tumor Gene 1 (WT1)–loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-09-01 / Anticancer Res 2010 Sep;30(9):3709-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-09-01 / Anticancer Res 2010 Sep;30(9):3709-142010-09-01 00:00:002024-03-18 10:58:36Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2002-01-10 / Cancer Immunol. Immunother. 2002 Mar;51(1):45-52
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2002-01-10 / Cancer Immunol. Immunother. 2002 Mar;51(1):45-522002-01-10 00:00:002019-02-15 08:46:11Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2002-01-07 / Br. J. Cancer 2002 Jan;86(1):151-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2002-01-07 / Br. J. Cancer 2002 Jan;86(1):151-72002-01-07 00:00:002002-01-07 00:00:00Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer
